1. Trang chủ
  2. » Luận Văn - Báo Cáo

Tài liệu Báo cáo Y học: Differential response of neuronal cells to a fusion protein of ciliary neurotrophic factor/soluble CNTF-receptor and leukemia inhibitory factor pot

9 445 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 9
Dung lượng 260,9 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Here, we report the construction and expression of a CNTF/soluble CNTF-receptor sCNTF-R fusion protein Hyper-CNTF with enhanced biological activity on cells expressing gp130 and leukemia

Trang 1

Differential response of neuronal cells to a fusion protein of ciliary neurotrophic factor/soluble CNTF-receptor and leukemia inhibitory factor

Pia Ma¨rz1,*, Suat O¨zbek2,*, Martina Fischer3, Nicole Voltz4, Uwe Otten1and Stefan Rose-John4,5

1

Department of Physiology, University of Basel, Switzerland;2Department of Biophysical Chemistry, Biocenter, University of Basel, Switzerland; 3 Xerion Pharmaceuticals, Martinsried, Germany; 4 Department of Medicine, Section Pathophysiology, Johannes Gutenberg University of Mainz, Germany; 5 Department of Biochemistry, Christian Albrechts University of Kiel, Germany

Ciliary neurotrophic factor (CNTF) displays neurotrophic

activities on motor neurons and neural cell populations both

in vivoand in vitro On target cells lacking intrinsic expression

of specific receptor a subunits cytokines of the IL-6 family

only act in the presence of their specific agonistic soluble

receptors Here, we report the construction and expression of

a CNTF/soluble CNTF-receptor (sCNTF-R) fusion protein

(Hyper-CNTF) with enhanced biological activity on cells

expressing gp130 and leukemia inhibitory factor receptor

(LIF-R), but not membrane-bound CNTF-R At the cDNA

level, the C-terminus of the extracellular domain of human

CNTF-R (amino acids 1–346) was linked via a single glycine

residue to the N-terminus of human CNTF (amino acids

1–186) Recombinant Hyper-CNTF protein was expressed

in COS-7 cells Hyper-CNTF efficiently induced

dose-dependent STAT3 phosphorylation and proliferation of

BAF-3 cells stably transfected with gp130 and LIF-R cDNAs While on BAF3/gp130/LIF-R cells, Hyper-CNTF and LIF exhibited similar biological responses, the activity

of Hyper-CNTF on pheochromocytoma cells (PC12 cells) was quite distinct from that of LIF In contrast to LIF, Hyper-CNTF stimulated neurite outgrowth of PC12 cells in

a time- and dose-dependent manner correlating with the ability to phosphorylate MAP kinases These data indicate that although LIF and Hyper-CNTF use the same heterodimeric receptor complex of gp130 and LIFR, only Hyper-CNTF induces neuronal differentiation The thera-peutic potential of Hyper-CNTF as a superagonistic neurotrophin is discussed

Keywords: cytokines; differentiation; rat; PC12 cells; signal transduction

Ciliary neurotrophic factor (CNTF) is a survival and

differentiation factor for a variety of neuronal and glial cells

It has been proposed to act as a lesion factor preventing

motor neuron degeneration after injury [1] and exerting

myotrophic activity on denervated skeletal muscle [2]

CNTF belongs to the IL-6 type family of neuropoietic

cytokines that comprises interleukin-6 (IL-6), interleukin-11

(IL-11), leukemia inhibitory factor (LIF), oncostatin M,

cardiotrophin-1 (CT-1), and novel neurotrophin-1

(NNT-1)/cardiotrophin-like cytokine (CLC) [3–7] All IL-6 type

cytokines use a membrane spanning 130-kDa glycoprotein,

gp130, as a signal transducing receptor subunit The

biological response to CNTF is elicited by formation of a

multimeric receptor complex [8] CNTF first binds

to a specific glycosyl-phosphatidylinositol-anchored a unit,

CNTF receptor (CNTF-R), which is not involved in signaling This is followed by the recruitment of gp130 and LIF receptor (LIF-R) as signal transducing b units, which in turn form a disulfide-linked heterodimer that activates the JAK/STAT and the Ras/MAP kinase path-ways [6,9] IL-6, CNTF as well as IL-11 and presumably CT-1 and NNT-1 act via specific membrane receptors which together with their ligands associate with signal transducing

b subunits thereby initiating cytoplasmic signaling Cells that only express signal transducing but no ligand binding subunits for these cytokines are refractory to stimulation

An unusual feature of the IL-6 cytokine family is that the soluble forms of the ligand binding receptor subunits generated by one cell type in complex with their ligands can directly stimulate the signal transducing receptor b subunits

on different cell types which lack ligand binding a subunits [10] This process has been named trans-signaling [11,12] The soluble form of CNTF-R (sCNTF-R) can be produced by limited proteolysis or by phospholipase C-mediated cleavage [13] Evidence for the importance of soluble cytokine receptors in neuronal signaling, differenti-ation and survival responses has accumulated (reviewed in [14])

Most recently, it was shown that the CNTF-R is also the cellular receptor for an additional cytokine, cardiotrophin-like cytokine (CLC) [15] This fact explains the different phenotype of CNTF–/– and CNTF-R–/– mice Whereas CNTF–/–mice show a mild phenotype [16] CNTF-R–/–mice die shortly after birth [17]

Correspondence to P Ma¨rz, Institute of Physiology,

University of Basel, Vesalgasse 1, CH-4051 Basel, Switzerland,

Fax: + 41 61 267 3559, Tel.: + 41 61 267 3553,

E-mail: p.maerz@unibas.ch

Abbreviations: CNTF, ciliary neurotrophic factor; sCNTF-R, soluble

CNTF receptor; IL-6, interleukin-6; LIF, leukemia inhibitory factor;

CT-1, cardiotrophin-1; NNT-1, novel neurotrophin-1; CLC,

cardiotrophin-like cytokine; JAK, Janus kinase; STAT, signal

transducer and activator of transcription; MAPK, mitogen activated

protein kinase; DMEM, Dulbecco’s modified Eagle’s medium.

*Note: these authors contributed equally to this work.

(Received 6 February 2002, revised 25 April 2002, accepted 3 May 2002)

Trang 2

Superagonistic cytokines have been designed that consist

of covalently linked cytokines and soluble receptors The

first such molecule was Hyper-IL-6, a fusion protein in

which IL-6 and soluble IL-6-R were connected by a flexible

polypeptide linker Hyper-IL-6 turned out to be fully active

on cells expressing gp130 at 100–1000 fold lower

concen-trations than unlinked IL-6 and sIL-6R [18] This approach

has been adopted to obtain a superagonist of IL-11 and

sIL-11R [19]

We generated a CNTF/soluble CNTF-receptor

(sCNTF-R) fusion protein with superagonistic activity on target cells

expressing gp130 and LIF-R, but lacking membrane-bound

CNTF-R In contrast to the existing cytokine–cytokine

receptor fusion proteins, Hyper-IL-6 and Hyper-IL-11,

which directly activate the ubiquitously expressed gp130

protein, such a protein allows more specificity due to the

restricted expression pattern of the LIF-R While the effects

of Hyper-CNTF and LIF on BAF3/-gp130/LIF-R cells

were similar, Hyper-CNTF but not LIF induced neuronal

differentiation of rat pheochromocytoma cells (PC12)

These data point to a cell-specific difference in signaling

via the heterodimeric receptor complex of gp130 and LIF-R

M A T E R I A L S A N D M E T H O D S

Chemicals

Dulbecco’s modified Eagle’s medium, penicillin and

strepto-mycin were purchased from Gibco (Eggenstein, Germany)

Fetal bovine serum was obtained from Seromed (Berlin,

Germany) DEAE-dextran was purchased from Sigma

(Taufkirchen, Germany) Restriction enzymes were from

New England Biolabs (Schwalbach, Germany) T4-DNA

ligase and polynucleotide kinase were purchased from

Boehringer Mannheim (Mannheim, Germany) Protein A

Sepharose was obtained from Pharmacia (Freiburg,

Germany) Tran-35 S-Label (44 TBqÆmmol)1) was from

ICN (Meckenheim, Germany) and [3H]thymidine (74

GBqÆmmol)1) was obtained from Amersham International

(Aylesbury, UK) X-ray films (X-OMAT-AR) were from

Eastman Kodak (Rochester, NJ)

Cells, cytokines and antibodies

PC12 and COS-7 cells (ATCC, Manassas, VA, USA),

BAF/3-gp130 cells (Immunex, Seattle, WA, USA) and

BAF/3-gp130/LIF-R cells [20] were grown in DMEM

with glutamax (Life Technologies, Inc., Karlsruhe,

Germany), supplemented with penicillin (50 UÆmL)1),

streptomycin (50 lgÆmL)1), and 10% fetal bovine serum

at 5% CO2 in a water saturated atmosphere

BAF/3-gp130 cells were cultured in the presence of 10 ngÆmL)1

Hyper-IL-6, BAF/3-gp130/LIF-R cells with 5 ngÆmL)1

human LIF Recombinant human IL-6 and human

CNTF were prepared as described previously [21,22]

The fusion protein hIL-6/hsIL-6R designated Hyper-IL-6

was expressed in the methylotrophic yeast Pichia pastoris

and purified to homogeneity by ion-exchange

chromatog-raphy followed by gelfiltration as described previously

[18,23] Nerve growth factor (NGF) was isolated [24] with

modifications as described previously [25] Recombinant

human LIF was expressed as glutathione S-transferase

(GST)-fusion protein, purified by glutathione Sepharose

4B and cleaved from GST by thrombin treatment as described by the manufacturer (Pharmacia, Freiburg, Germany) The fusion proteins gp130-Fc and LIF-R-Fc were transiently expressed in COS-7 cells and purified by protein A-Sepharose, as described previously [26,27] Recombinant growth factor concentrations were estimated using standard protein assays The polyclonal anti-(phos-pho-STAT3) Ig and anti-(phospho-p44/42 MAP kinase)

Ig were from New England Biolabs (Schwalbach, Germany) The monoclonal anti-(CNTF-R) Ig (AN-D3) was a kind gift of H Gascan (Angers, France) [28] Construction of Hyper-CNTF expression plasmid The cDNA sequences of human CNTF-R encoding the Ig-like domain and the cytokine binding domains (cor-responding to amino acids 1–346) and human CNTF (corresponding to amino acids 1–186) were amplified by standard PCR technique Using oligonucleotide primers, XbaI and SmaI restriction sites were introduced at the 5¢ and 3¢ ends of the CNTF and CNTF-R cDNAs, respectively The primer sequences used are available from the authors upon request After digestion, both PCR products were ligated simultaneously into the XbaI site of the pcDNA3.1(–) expression vector (Invitrogen, San Diego, CA, USA) Ligation at SmaI led to the insertion

of three additional nucleotides coding for glycine The integrity of the construct was verified by restriction fragment analysis and DNA sequencing according to standard protocols [29]

Expression of Hyper-CNTF in COS-7 cells COS-7 cells were transiently transfected with plasmids coding for either Hyper-CNTF or b-galactosidase as control

by the DEAE-Dextran technique, essentially as described previously [30] For immunoprecipitations, Hyper-CNTF transfected cells were cultured for 48 h and metabolically labeled with 50 lCiÆmL)1 [35S]methionine/[35S]cysteine (Tran-35S-Label) in methionine/cysteine-free medium for

6 h For production of Hyper-CNTF protein, transfected cells were transferred to serum-free medium after 24 h and supernatants were collected on day 4 post-transfection Immunoprecipitation

Metabolically labeled Hyper-CNTF was precipitated from culture media using 0.5 lgÆmL)1 gp130-Fc, 0.5 lgÆmL)1 LIF-R-Fc or 1 lgÆmL)1 monoclonal anti-CNTF-R Ig (AN-D3) followed by protein A–Sepharose Immune complexes were analyzed by SDS/PAGE [31] and visual-ized by fluorography using the fluorographic intensifier solution Amplify (Amersham International, Aylesbury, UK)

Proliferation assays BAF/gp130 and BAF/gp130/LIF-R cells were extensively washed with NaCl/Pi, and resuspended in cytokine free medium at 5· 103cells per well of a 96-well plate They were cultured in a final volume of 100 lL with cytokines as indicated in the figure legends for 68 h and subsequently pulse labeled with 0.25 lCi [3H]thymidine for 4 h Cells

Trang 3

were harvested on glass filters and incorporated [3H]

thymidine was determined by scintillation counting

Inde-pendent bioassays were performed three times with each

value being determined in duplicate

Neurite outgrowth

Neurite outgrowth assays were performed in six-well plates

PC12 cells were grown in complete media in the presence of

growth factors as indicated The percentage of responsive

cells characterized by neurites extending longer than twice

the diameter of cell bodies was scored The scale of

microphotographs is indicated in the figure legends as fold

magnification

Western Blot analysis

Proteins from cell lysates of transfected BAF/3 or PC12 cells

were separated by SDS/PAGE and transferred onto

poly(vinylidine fluoride) membranes by electroblotting

Phosphorylated STAT3 and p44/42 MAP kinases (New

England Biolabs, Schwalbach, Germany), were detected

using polyclonal rabbit (phospho-STAT3) Ig and

anti-(phospho-p44/42 MAP kinase) Ig As secondary reagent,

horseradish peroxidase (HRP)-conjugated goat anti-(rabbit

IgG) Ig was used (Sigma, Deisenhofen, Germany) The blot

was developed using the ECL-detection system (Amersham

International, Aylesbury, UK) The STAT3 and MAPK

phosphorylation assays were reproduced three times with

one representative experiment shown

R E S U L T S

Construction of CNTF/sCNTF-R fusion protein

We engineered an expression vector encoding a CNTF/

sCNTF-R fusion protein by linking the C-terminus of

human CNTF-R to the N-terminus of human CNTF

(Fig 1A) In principle, we followed the design of

Hyper-IL-6 [18] with two specific modifications First, we included

the N-terminal Ig domain of the sCNTF-R, as deletion of

this region lead to reduced expression levels of recombinant

sCNTF-RDIg protein (P Ma¨rz, M Fischer & S

Rose-John, unpublished work) This observation is in line with

recent results indicating that the Ig-like domain of the IL-6R

is important for intracellular transport of IL-6R through the

secretory pathway [32] Secondly, we avoided the use of a

synthetic polypeptide linker in order to minimize

immun-ogenicity Instead, the 16 C-terminal amino acids of

CNTF-R (amino acids 331–346) that are not part of the

membrane-proximal cytokine binding domain [33] and the

14 N-terminal nonhelical and presumably flexible amino

acids of CNTF (amino acids 1–12) [34] were linked by one

additional glycine residue The resulting length of 31 amino

acids, in analogy to Hyper-IL-6 and Hyper-IL-11, is

presumably sufficient to connect both molecules and to

allow access of CNTF to its CNTF-R binding site In a

similar approach, we have recently reduced the length of the

Hyper-IL-6 linker without apparent loss of biological

function [35] A schematic model of the anticipated tertiary

structure of the CNTF/sCNTF-R fusion protein is shown in

Fig 1B

Expression of CNTF/sCNTF-R fusion protein and interaction with the signal transducing b-subunits gp130 and LIF-R

Expression of Hyper-CNTF protein was performed by transient transfection of COS-7 cells Cleavage of the endogenous CNTF-R signal peptide in transfected COS cells led to the secretion of the fusion protein Hyper-CNTF into the supernatant As shown in Fig 2A, the Hyper-CNTF fusion protein, with an apparent molecular mass of

 82 kDa, was detected by Western blot analysis with a CNTF antiserum Supernatant from mock transfected COS-7 cells expressing the b-Gal gene did not show any signal detected by the CNTF antiserum Immunodetection with this antibody also serves as control for complete translation and integrity of Hyper-CNTF protein because it recognizes the C-terminal CNTF moiety of the newly generated protein After transfection of COS-7 cells with the Hyper-CNTF expression plasmid, metabolically35S-labeled Hyper-CNTF protein could be precipitated from the super-natant with a monoclonal anti-(CNTF-R) Ig (Fig 2B) To test for physical interaction with the signal transducing

b subunits of the CNTF-R system, the35S-labeled Hyper-CNTF protein was incubated with Fc-fusion proteins containing the extracellular portion of gp130 or the extracellular portion of LIF-R Protein complexes were precipitated with protein A-Sepharose As can be seen

in Fig 2B, Hyper-CNTF interacted with gp130-Fc and LIF-R-Fc to a similar extent

Fig 1 Schematic representation of the fusion protein of CNTF and sCNTF-R (A) Construction of the fusion protein The C-terminus of sCNTF-R was linked via one additional glycine residue (G) to the N-terminus of CNTF (B) Schematic model of the Hyper-CNTF ter-tiary structure Ig denotes the immunoglobulin-like domain, D2 and D3 the two cytokine-binding receptor domains.

Trang 4

Biological activity of the Hyper-CNTF fusion protein

To assess the biological activity of Hyper-CNTF, we first

investigated the proliferative response of transfected BAF/3

cells Murine BAF/3 cells, which normally grow

IL-3-dependently, are known to proliferate in response to various

cytokines after transfection of the corresponding receptor

chains BAF/3 cells transfected with human gp130 and/or

additional transfection of the human LIF-R were stimulated

with increasing amounts of Hyper-IL-6, Hyper-CNTF, LIF

or medium alone Proliferation of cells was assayed by measuring [3H]thymidine incorporation into DNA As shown in Fig 3A, BAF/3-gp130 cells proliferate upon stimulation with Hyper-IL-6, but absence of the LIF-R prevented a proliferative activity of LIF as well as of Hyper-CNTF on these cells In contrast, on BAF/3-gp130/LIF-R cells Hyper-IL-6, LIF and Hyper-CNTF were fully active (Fig 3B) These data indicate that fusion of CNTF to its respective soluble CNTF-R resulted in a protein conferring responsiveness of cells that lack membrane-bound CNTF-R and thus are usually inert to stimulation by CNTF The most significant finding, however, is that Hyper-CNTF has virtually the same activity as LIF as well as Hyper-IL-6; half-maximal activity was obtained with cytokine concen-trations of 5–10 pgÆmL)1 Accordingly, Hyper-CNTF rep-resents a protein with greatly enhanced bioactivity requiring heterodimerization of the b-receptor subunits gp130 and LIF-R

Fig 2 Interaction of the Hyper-CNTF protein with the signaling

receptor subunits gp130 and LIF-R (A) Immunodetection of

Hyper-CNTF protein in the supernatants of transiently transfected COS-7

cells The C-terminal CNTF moiety of the fusion protein was detected

with a polyclonal CNTF antiserum [22] Recombinant human CNTF

(at 26 kDa) was blotted as positive control and supernatant from

mock transfected COS-7 cells expressing the b-gal gene served as

negative control (B) Metabolically labeled Hyper-CNTF was

preci-pitated from cell supernatants with gp130-Fc, LIFR-Fc proteins or a

monoclonal anti-(CNTF-R) Ig Immune complexes precipitated with

protein A–Sepharose were separated by SDS/PAGE and visualized by

fluorography Electrophoretic mobilities of molecular mass marker

proteins are indicated on the left.

Fig 3 Proliferative response of transfected BAF/3 cells to Hyper-CNTF (A) BAF/3-gp130 cells and (B) BAF/3-gp130/LIF-R cells were stimulated with increasing amounts of Hyper-CNTF, Hyper-IL-6, LIF

or medium alone Proliferation of cells was assayed by measuring [ 3 H]thymidine incorporation into DNA One representative experi-ment is shown.

Trang 5

STAT3 and MAPK activation by Hyper-CNTF

in transfected BAF/3 cells

Downstream signal transduction pathways were analyzed

by studying the activation level of JAK/STAT and MAP

kinase signaling components known to be mainly tyrosine

phosphorylated in response to IL-6 type cytokines [36–38]

BAF/3-gp130 cells and BAF/3-gp130/LIF-R cells were

stimulated with medium alone, 10 ngÆmL)1 Hyper-IL-6,

20 ngÆmL)1 Hyper-CNTF, 50 ngÆmL)1 IL-6, 50 ngÆmL)1

CNTF or 20 ngÆmL)1LIF for 10 min (Fig 4) Cells were

lysed in Laemmli buffer and proteins were separated via

SDS/PAGE and blotted onto poly(vinylidine fluoride)

membranes Membranes were cut into two pieces below

the 62-kDa marker band and phosphorylated STAT3

proteins were detected on the upper part of the membrane

using a phosphospecific anti-STAT3 Ig Analogously,

phosphorylated MAP kinases were detected on the lower

part of the membrane by use of a phospho-p44/42 MAP

kinase antibody followed by ECL detection As shown in

Fig 4, a 10-min stimulation of BAF/3-gp130 cells with

Hyper-IL-6 led to pronounced tyrosine phosphorylation of

STAT3 and p42/p44 MAP kinases The same activation

pattern was observed after stimulation of BAF/3-gp130/

LIF-R cells with Hyper-IL-6, Hyper-CNTF and LIF No

phosphorylation could be detected upon stimulation of the

cells with CNTF or IL-6, reflecting the lack of the specific

ligand binding receptor subunits or medium alone in none

of the two transfected BAF/3 cell lines These data indicate

that on BAF/3 cells, the composite cytokines Hyper-IL-6

and Hyper-CNTF as well as LIF recruit the same signal

transduction pathways for induction of proliferation

with-out any receptor-specific differences

Neuronal differentiation of PC12 cells by Hyper-CNTF

In a second bioassay, we investigated the potential role

of Hyper-CNTF in neuronal cell differentiation The

morphology of rat pheochromocytoma cells (PC12) grown for 48 h in serum-containing medium in the absence of factors (medium) or in the presence of 100 ngÆmL)1CNTF,

20 ngÆmL)1Hyper-CNTF, 100 ngÆmL)1LIF, 100 ngÆmL)1 NGF or 20 ngÆmL)1Hyper-IL-6 was analysed As expected from earlier studies [39,40], stimulation of the cells with NGF or Hyper-IL-6 led to robust formation of neurites Surprisingly, exposure of the cells to Hyper-CNTF also induced pronounced neuronal differentiation, whereas LIF and CNTF (at concentrations up to 500 ngÆmL)1, data not shown) did not result in significant morphological changes (Fig 5A) Hyper-CNTF induced neurites extending longer than twice the diameter of the cell bodies appear within a day, and maximal response is reached in 2 days For direct comparison, the amount of responsiveness was evaluated for all factors at 48 h As presented in Fig 5B, Hyper-CNTF turned out to be virtually as effective as NGF and Hyper-IL-6 to elicit neuronal differentiation

STAT3 and MAPK activation by Hyper-CNTF in PC12 cells

We then asked which signal transduction pathways are involved in Hyper-CNTF-induced neurite outgrowth In a first experiment, PC12 cells were stimulated with medium alone, Hyper-IL-6, NGF, Hyper-CNTF, or LIF for 10 min (Fig 6A) Cells were lysed in Laemmli buffer and cell lysates

Fig 4 STAT3 and MAPK phosphorylation by Hyper-CNTF in

transfected BAF/3 cells (A) BAF/3-gp130 cells and (B) BAF/3-gp130/

LIF-R cells were stimulated with medium alone, 10 ngÆmL)1

Hyper-IL-6, 20 ngÆmL)1Hyper-CNTF, 50 ngÆmL)1IL-6, 50 ngÆmL)1CNTF

or 20 ngÆmL)1LIF for 10 min Cells were lysed in Laemmli buffer and

proteins were separated via SDS/PAGE and blotted onto PVDF

membranes Membranes were probed for phosphorylated STAT3 and

MAP kinases (p44/p42) using phospho-specific antibodies and ECL

detection.

Fig 5 Neuronal differentiation of PC12 cells by Hyper-CNTF (A) Morphology of PC12 cells grown for 48 h in serum-containing medium in the absence of factors (medium) or in the presence of

100 ngÆmL)1CNTF, 20 ngÆmL)1Hyper-CNTF, 100 ngÆmL)1LIF,

100 ngÆmL)1NGF or 20 ngÆmL)1Hyper-IL-6 was analyzed (magni-fication: 300·) and (B) the extent of responsiveness was evaluated by analysis of neurite outgrowth Vertical bars represent S.E.M (n ¼ 3).

Trang 6

were analyzed for STAT3 and MAPK phosphorylation as

described above We found that stimulation with

Hyper-IL-6 led to an increase of both, STAT3 and MAPK

phos-phorylation Consistent with other reports [41,42], a strong

activation of p42/p44 MAP kinases was observed by NGF

Interestingly, as compared to Hyper-IL-6, treatment of the

cells with Hyper-CNTF resulted in small but significant

STAT3 phosphorylation and strong MAPK

phosphoryla-tion which was at least equal to Hyper-IL-6 In contrast,

stimulation with LIF alone had a similar effect on STAT3

phosphorylation but no effect on MAP kinase activation As

demonstrated in Fig 6B, the dose–response

phosphoryla-tion pattern for both STAT3 and p42/p44 MAP kinases

clearly confirmed that of the cytokines signaling through

gp130/LIF-R only Hyper-CNTF but not LIF or CNTF

(even at high concentrations) alone were able to activate the MAPK pathway MAP kinases and STAT3 are rapidly activated within 10 min in response to Hyper-CNTF, the phase of activation lasting for at least 30 min before returning to near basal levels within 1 h (Fig 6C) These data are in line with the different abilities of Hyper-CNTF, LIF and CNTF to induce neuronal differentiation in PC12 cells, as observed above We conclude that the Hyper-CNTF-induced neurite outgrowth is most likely mediated by activation of the MAPK pathway and that this response is substantially independent of the JAK/STAT pathway

D I S C U S S I O N

We have successfully expressed an active fusion protein of human CNTF and human soluble CNTF-R in mammalian cells Hyper-CNTF has a calculated molecular mass of

60 kDa and apparent molecular mass of 85 kDa, the increase being most likely due to heavy glycosylation (four N-linked glycosylation sites) Expression of Hyper-CNTF circumvents the use of high amounts of recombinant CNTF and soluble CNTF-R since the concentrations of the two separate components needed for full stimulation is 1–2 orders of magnitude higher than that of Hyper-CNTF [13] The Hyper-CNTF protein was precipitated using Fc fusion proteins of the extracellular portion of gp130 and LIF-R [26] This result confirms the structural integrity of the Hyper-CNTF protein since the CNTF/sCNTF-R complex has been reported to interact with the LIF-R Direct binding of the CNTF/sCNTF-R complex to gp130 has not been previously described It has been noted, however, that LIF bound not only to the LIF-R but also to the gp130 protein albeit with low affinity [43–45]

Cells that only express gp130 and LIF-R, but not

CNTF-Ra are refractory to stimulation by CNTF As expected, BAF/3-gp130 cells lacking LIF-R were neither responsive to Hyper-CNTF nor to LIF Hyper-CNTF induced prolifer-ation of BAF/3 cells expressing gp130 and LIF-R at virtually the same concentration as LIF and Hyper-IL-6 needed to achieve half-maximal activity The signaling events of stimulated BAF/3 cells reflected by the activation pattern of STAT3 and MAP kinases, mainly p42, were identical for BAF/3 cells stimulated with Hyper-IL-6, Hyper-CNTF, and LIF

Analysis of the biological activity of Hyper-CNTF in non-neuronal vs neuronal cells revealed unexpected func-tional and biochemical differences between LIF and Hyper-CNTF activity In contrast to LIF, Hyper-Hyper-CNTF rapidly induced neurite outgrowth and formation of a neuronal network in PC12 cells Looking at the signaling events, we observed that both LIF and Hyper-CNTF induced phos-phorylation of STAT3 However, only Hyper-CNTF has the potential to activate MAP kinases This finding is in agreement with the experiments of Sterneck et al who failed

to induce neuronal differentiation with CNTF and LIF in PC12 cells [46,47]

How can the differential response of BAF/3 cells and PC12 cells be explained? The phenomenon that stimulation

of the gp130/LIF-R complex by different cytokines might result in different biological responses in neuronal cells has already been discussed in a review [48] It is known that gp130 stimulation leads to the activation of multiple signaling cascades including the STAT3 and the MAPK

Fig 6 STAT3 and MAPK activation by Hyper-CNTF in PC12 cells.

PC12 cells were stimulated with medium alone, 20 ngÆmL)1

Hyper-IL-6, 100 ngÆmL)1NGF, 20 ngÆmL)1Hyper-CNTF, or 50 ngÆmL)1LIF

for 10 min Cells were lysed in Laemmli buffer and cell lysates were

analyzed for STAT3 and MAPK (p44/p42) phosphorylation as

des-cribed in the legend to Fig 4 (B) Dose–response of

Hyper-CNTF-induced phosphorylation of STAT3 and MAP kinases in comparison

to CNTF alone, LIF, NGF and Hyper-IL-6 (C) PC12 cells were

activated with 50 ngÆmL)1Hyper-CNTF for 10 min up to 4 h After

lysis, whole cell extracts were Western blotted and their STAT3 and

MAP kinase tyrosine phosphorylation levels were determined.

Trang 7

pathway Gp130 activation on different cells can have

multiple physiological consequences such as stimulation of

proliferation, stimulation of differentiation, prevention of

differentiation, prevention of apoptosis and activation of a

family of genes coding for the acute phase proteins [6,49]

The different physiological responses are thought to result

from differential activation of the different intracellular

signal transduction pathways [9,50] It is not clear to date,

whether these differences are quantitative or temporal In

other words, signal transduction components might be

overexpressed or underexpressed in different cells

Alter-natively, the duration of activation of the distinct signal

transduction pathways might be differentially regulated [50]

Interestingly, we have observed that HepG2 cells stimulated

by Hyper-IL-6 showed a more profound and elongated

response as compared to IL-6 [51] This was most likely due

to decreased internalization of Hyper-IL-6 as compared to

IL-6 We have also recently described differential effects of

IL-6 and Hyper-IL-6 on PC12 cells Whereas PC12 cells

responded to both IL-6 and Hyper-IL-6 with an increase in

expression of growth associated protein (GAP)-43 mRNA

and protein, only Hyper-IL-6 induced neuronal

differenti-ation in these cells [39] Intriguingly, it has been shown by

Ihara et al 1997 [52] that gp130 mutants incapable of

activating the MAPK pathway failed to induce neurite

outgrowth Consistently, a MAPK kinase inhibitor,

PD98059, inhibited neurite outgrowth These results suggest

that the activation of the MAPK pathway is essential for

gp130 induced neurite outgrowth of PC12 cells whereas

STAT3 is believed to inhibit this response [52,53] In line

with these findings, Hyper-CNTF led to a profound

activation of the MAPK pathway with little stimulation

of STAT3 We therefore conclude that upon receptor

stimulation by Hyper-CNTF and LIF in PC12 cells, the

intracellular signal transduction pathways diverge leading to

the observed differences in physiological response in

neur-onal cells The underlying molecular mechanism might

include the recruitment of the transducing proteins through

binding of Hyper-CNTF and LIF to distinct functional

motifs in the extracellular region of the receptor, leading to

minor conformational changes in the cytoplasmic domains

Strobl et al were able to show that for comparable levels of

STAT1 phosphorylation by slightly different chimeric

gp130 receptors, significantly changed transcriptional

responses could be observed indicative for a qualitative

change in the signaling pathway [54]

The newly constructed Hyper-CNTF molecule has two

main advantages over the Hyper-IL-6 and Hyper-IL-11

constructs First, the spectrum of target cells is more

restricted All cells in the body express gp130, whereas only

some cells including most cells of the nervous system express

the LIF-R [14] Therefore, Hyper-CNTF seems to be more

suited for an in vivo application than Hyper-IL-6 Secondly,

the fusion protein Hyper-CNTF does not contain a

synthetic polypeptide linker, the CNTF-R and CNTF being

linked via the flexible C-terminal portion of the CNTF-R

and the N-terminal part of CNTF [33,34] with only a single

additional amino-acid residue introduced We speculate

that this protein will not be recognized by the immune

system as a foreign protein and should not lead to major

immune responses

IL-6 type cytokines have been shown to possess robust

neurotrophic activity [14,55–60] Our data indicate that

Hyper-CNTF in addition to its superagonistic activity, possesses a unique property over LIF Therefore, the possible heightened therapeutic potential of Hyper-CNTF will have to be tested for nerve regeneration after axotomy and long-term survival of spinal motoneurons in animal models

Administration of CNTF has been shown in various models with neuromuscular dysfunction to elicit neuropro-tective effects For example, CNTF can rescue many motor neurons in progressive motor neuronopathy pmn mice, a spontaneous mutant with motor neuronopathy Moreover, CNTF has been demonstrated to slow the progression of motor dysfunction in wobbler mice, another animal model for motor neuron disease [61] These findings encouraged the use of CNTF and related neuropoietic cytokines in human motor disease The interest in the neuroprotective potential of gp130/LIF-R stimulation has been revived by the demonstration that the CNTF-R not only complexes with CNTF but also with the newly identified cytokine CLC [15]

Recently it has been shown that delivery using CNTF-releasing implants, as described by Aebischer et al [62–64], was efficient to treat motor neuron disease in animals We propose that similar implants containing recombinant Hyper-CNTF protein could represent a more optimal way

to stimulate degenerating neuronal cells in amyotrophic lateral sclerosis or other neurological diseases

A C K N O W L E D G E M E N T S

We thank Dr Birgit Oppmann, Dr Marc Ehlers and Dr Barbara Krebs for the production of recombinant LIF and CNTF, Dr Thomas Jostock for cloning of the LIF-R-Fc fusion construct and Dr Hughes Gascan for the CNTF-R antibody This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany), the Stiftung Rheinland Pfalz fu¨r Innovation (Mainz, Germany) and the Naturwissenschaftlich-Medizinisches Forschungszentrum (Mainz, Germany) to S R.-J., and from the Swiss National Foundation for Scientific Research (Grant 3100-061571.00/1) and the Deutsche Forschungsgemeinschaft (SFB505/B5) to U O.

R E F E R E N C E S

1 Sendtner, M., Go¨tz, R., Holtmann, B & Thoenen, H (1997) Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motoneurons in adult mice J Neurosci 17, 6999– 7006.

2 Sleeman, M.W., Anderson, K.D., Lambert, P.D., Yancopoulos, G.D & Wiegand, S.J (2000) The ciliary neurotrophic factor and its receptor, CNTFR alpha Pharm Acta Helv 74, 265–272.

3 Bazan, J.F (1990) Haemopoietic receptors and helical cytokines Immunol Today 11, 350–354.

4 Fann, M.J & Patterson, P.H (1994) Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sym-pathetic neurons Proc Natl Acad Sci USA 91, 43–47.

5 Hibi, M., Nakajima, K & Hirano, T (1996) IL-6 cytokine family and signal transduction: a model of the cytokine system J Mol Med 74, 1–12.

6 Taga, T & Kishimoto, T (1997) gp130 and the Interleukin-6 Family of Cytokines Annu Rev Immunol 15, 797–819.

7 Senaldi, G., Varnum, B.C., Sarmiento, U., Starnes, C., Lile, J., Scully, S., Guo, J., Elliott, G., McNinch, J., Shaklee, C.L et al (1999) Novel neurotrophin-1/B cell-stimulating factor-3: a cyto-kine of the IL-6 family Proc Natl Acad Sci USA 96, 11458– 11463.

Trang 8

8 Davis, S., Aldrich, T.H., Stahl, N., Pan, L., Taga, T., Kishimoto,

T., Ip, N.Y & Yancopoulos, G.D (1993) LIFR beta and gp130 as

heterodimerizing signal transducers of the tripartite CNTF

receptor Science 260, 1805–1808.

9 Hirano, T (1999) Molecular basis underlying functional

pleiot-ropy of cytokines and growth factors Biochem Biophys Res.

Commun 260, 303–308.

10 Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K.,

Matsuda, T., Hirano, T & Kishimoto, T (1989) Interleukin-6

triggers the association of its receptor with a possible signal

transducer, gp130 Cell 58, 573–581.

11 Rose-John, S & Heinrich, P.C (1994) Soluble receptors for

cytokines and growth factors: generation and biological function.

Biochem J 300, 281–290.

12 Mu¨llberg, J., Althoff, K., Jostock, T & Rose-John, S (2000) The

importance of shedding of membrane proteins for cytokine

biol-ogy Eur Cyt Netw 11, 27–38.

13 Davis, S., Aldrich, T.H., Ip, N.Y., Stahl, N., Scherer, S.,

Farruggella, T., DiStefano, P.S., Curtis, R., Panayotatos, N.,

Gascan, H., Chevalier, S & Yancopulos, G.D (1993) Released

form of CNTF receptor alpha component as a soluble mediator of

CNTF responses Science 259, 1736–1739.

14 Ma¨rz, P., Otten, U & Rose-John, S (1999) Neuronal activities of

IL-6 type cytokines often depend on soluble cytokine receptors.

Eur J Neurosci 11, 2995–3004.

15 Elson, G.C., Lelievre, E., Guillet, C., Chevalier, S., Plun-Favreau,

H., Froger, J., Suard, I., de Coignac, A.B., Delneste, Y.,

Bonne-foy, J.Y., Gauchat, J.F & Gascan, H (2000) CLF associates with

CLC to form a functional heteromeric ligand for the CNTF

receptor complex Nat Neurosci 3, 867–872.

16 Masu, Y., Wolf, E., Holtmann, B., Sendtner, M., Brem, G &

Thoenen, H (1993) Disruption of the CNTF gene results in motor

neuron degeneration Nature 365, 27–32.

17 DeChiara, T.M., Vejsada, R., Poueymirou, W.T., Acheson, A.,

Suri, C., Conover, J.C., Friedman, B., McClain, J., Pan, L., Stahl,

N et al (1995) Mice lacking the CNTF receptor, unlike mice

lacking CNTF, exhibit profound motor neuron deficits at birth.

Cell 83, 313–322.

18 Fischer, M., Goldschmitt, J., Peschel, C., Kallen, K.J.,

Brakenh-off, J.P.J., Wollmer, A., Gro¨tzinger, J & Rose-John, S (1997)

A designer cytokine with high activity on human hematopoietic

progenitor cells Nat Biotechnol 15, 142–145.

19 Pflanz, S., Tacken, I., Gro¨tzinger, J., Jacques, Y., Dahmen, H.,

Heinrich, P.C & Mu¨ller-Newen, G (1999) A fusion protein of

interleukin-11 and soluble interleukin-11 receptor acts as a

superagonist on cells expressing gp130 FEBS Lett 450, 117–122.

20 Kallen, K.-J., Gro¨tzinger, J., Lelie`vre, E., Vollmer, P., Aasland,

D., Renne´, C., Mu¨llberg, J., Meyer zum Bu¨schenfelde, K.-H.,

Gascan, H & Rose-John, S (1999) Receptor recognition sites of

cytokines are organized as exchangeable modules: transfer of the

LIFR binding site from CNTF to IL-6 J Biol Chem 274, 11859–

11867.

21 van Dam, M., Mu¨llberg, J., Schooltink, H., Stoyan, T.,

Brakenhoff, J.P., Graeve, L., Heinrich, P.C & Rose-John, S.

(1993) Structure-function analysis of interleukin-6 utilizing

human/murine chimeric molecules Involvement of two separate

domains in receptor binding J Biol Chem 268, 15285–15290.

22 Kru¨ttgen, A., Gro¨tzinger, J., Kurapkat, G., Weis, J., Simon, R.,

Thier, M., Schro¨der, M., Heinrich, P., Wollmer, A., Comeau, M.,

Mu¨llberg, J & Rose-John, S (1995) Human ciliary neurotrophic

factor: a structure–function analysis Biochem J 309, 215–220.

23 Vollmer, P., Peters, M., Ehlers, M., Yagame, H., Matsuba, T.,

Kondo, M., Yasukawa, K., Bu¨schenfelde, K.H & Rose-John, S.

(1996) Yeast expression of the cytokine receptor domain of the

soluble interleukin-6 receptor J Immunol Methods 199, 47–54.

24 Bocchini, V & Angeletti, P.U (1969) The nerve growth factor: purification as a 30,000-molecular-weight protein Proc Natl Acad Sci USA 64, 787–794.

25 Weskamp, G & Otten, U (1987) An enzyme-linked immunoassay for nerve growth factor (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and in per-ipheral tissues J Neurochem 48, 1779–1786.

26 Jostock, T., Blinn, G., Renne´, C., Kallen, K.-J., Rose-John, S & Mu¨llberg, J (1999) Immunoadhesins of IL-6 and Hyper-IL-6.

J Immunol Methods 223, 171–183.

27 Atreya, R., Mudter, J., Finotto, S., Mu¨llberg, J., Jostock, T., Wirtz, S., Schu¨tz, M., Bartsch, B., Holtmann, M., Becker, C et al (2000) Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells Nat Med 6, 583–588.

28 Fraysse, B., Guillet, C., Huchet-Cadiou, C., Camerino, D.C., Gascan, H & Leoty, C (2000) Ciliary neurotrophic factor pre-vents unweighting-induced functional changes in rat soleus mus-cle J Appl Physiol 88, 1623–1630.

29 Sambrook, J., Fritsch, E.F & Maniatis, T (1989) Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

30 McMahan, C.J., Slack, J.L., Mosley, B., Cosman, D., Lupton, S.D., Brunton, L.L., Grubin, C.E., Wignall, J.M., Jenkins, N.A., Brannan, C.I et al (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types EMBO J 10, 2821–2832.

31 Laemmli, U.K (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227, 680–685.

32 Vollmer, P., Oppmann, B., Voltz, N., Fischer, M & Rose-John, S (1999) A role for the immunoglobulin-like domain of the human IL-6 receptor: intracellular protein transport and shedding Eur J Biochem 263, 438–446.

33 Davis, S., Aldrich, T.H., Valenzuela, D.M., Wong, V.V., Furth, M.E., Squinto, S.P & Yancopoulos, G.D (1991) The receptor for ciliary neurotrophic factor Science 253, 59–63.

34 McDonald, N.Q., Panayotatos, N & Hendrickson, W.A (1995) Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing EMBO J 14, 2689–2699.

35 Chebath, J., Fischer, D., Kumar, A., Oh, J.W., Kolett, O., Lapidot, T., Fischer, M., Rose-John, S., Nagler, A., Slavin, S & Revel, M (1997) Interleukin-6 receptor-interleukin-6 fusion pro-teins with enhanced interleukin-6 type pleiotropic activities Eur Cyt Netw 8, 359–365.

36 Fukada, T., Hibi, M., Yamanaka, Y., Takahashi Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K & Hirano, T (1996) Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis Immunity 5, 449–460.

37 Hirano, T., Ishihara, K & Hibi, M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Oncogene

19, 2548–2556.

38 Ihle, J.N (2001) The Stat family in cytokine signaling Curr Opin Cell Biol 13, 211–217.

39 Ma¨rz, P., Herget, T., Lang, E., Otten, U & Rose-John, S (1997) Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation Eur J Neurosci 9, 2765–2773.

40 Hoischen, S.H., Vollmer, P., Ma¨rz, P., O¨zbek, S., Go¨tze, K., Jostock, T., Geib, T., Mu¨llberg, J., Mechtersheimer, S., Fischer, M., Gro¨tzinger, J., Galle, P.R & Rose-John, S (2000) Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells Eur J Biochem 267, 3604–3612.

41 Cowley, S., Paterson, H., Kemp, P & Marshall, C.J (1994) Activation of MAP kinase is necessary and sufficient for PC12

Trang 9

differentiation and for transformation of NIH3T3 cells Cell 77,

841–852.

42 Pang, L., Sawada, T., Decker, S.J & Saltiel, A.R (1995)

Inhibi-tion of MAP kinase blocks the differentiaInhibi-tion of PC-12 cells

induced by nerve growth factor J Biol Chem 270, 13585–13588.

43 Hudson, K.R., Vernallis, A.B & Heath, J.K (1996)

Character-ization of the receptor binding sites of human leukemia inhibitory

factor and creation of antagonists J Biol Chem 271, 11971–

11978.

44 Vernalis, A.B., Hudson, K.R & Heath, J.K (1997) An antagonist

for the leukemia inhibitory factor receptor inhibits leukemia

inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and

oncostatin M J Biol Chem 272, 26947–26952.

45 Bravo, J & Heath, J.K (2000) Receptor recognition by gp130

cytokines EMBO J 19, 2399–2411.

46 Sterneck, E., Kaplan, D.R & Johnson, P.F (1996) Interleukin-6

induces expression of peripherin and cooperates with Trk receptor

signaling to promote neuronal differentiation in PC12 cells.

J Neurochem 67, 1365–1374.

47 Wu, Y.Y & Bradshaw, R.A (1996) Induction of neurite

out-growth by interleukin-6 is accompanied by activation of Stat3

signaling pathway in a variant PC12 cell (E2) line J Biol Chem.

271, 13023–13032.

48 Murphy, M., Dutton, R., Koblar, S., Cheema, S & Bartlett, P.

(1997) Cytokines which signal through the LIF receptor and their

actions in the nervous system Prog Neurobiol 52, 355–378.

49 Shirogane, T., Fukada, T., Muller, J.M., Shima, D.T., Hibi, M &

Hirano, T (1999) Synergistic roles for Pim-1 and c-Myc in

STAT3-mediated cell cycle progression and antiapoptosis.

Immunity 11, 709–719.

50 Hirano, T., Nakajima, K & Hibi, M (1997) Signaling

mechan-isms through gp130: a model of the cytokine system Cytokine

Growth Factor Rev 4, 241–252.

51 Peters, M., Blinn, G., Solem, F., Fischer, M., Meyer zum

Bu¨s-chenfelde, K.-H & Rose-John, S (1998) In vivo and in vitro

activity of the gp130 stimulating designer cytokine hyper-IL-6.

J Immunol 161, 3575–3581.

52 Ihara, S., Nakajima, K., Fukada, T., Hibi, M., Nagata, S.,

Hirano, T & Fukui, Y (1997) Dual control of neurite outgrowth

by STAT3 and MAP kinase in PC12 cells stimulated with

inter-leukin-6 EMBO J 16, 5345–5352.

53 Fukada, T., Ohtani, T., Yoshida, Y., Shirogane, T., Nishida, K.,

Nakajima, K., Hibi, M & Hirano, T (1998) STAT3 orchestrates

contradictory signals in cytokine-induced G1 to S cell-cycle

tran-sition EMBO J 17, 6670–6677.

54 Strobl, B., Arulampalam, V., Is’harc, H., Newman, J., Schlaak,

J.F., Watling, D., Costa-Pereira, A.P., Schaper, F., Behrmann, I.,

Sheehan, C.F et al (2001) A completely foreign receptor can mediate an interferon-c-like response EMBO J 20, 5431–5442.

55 Hirota, H., Kiyama, H., Kishimoto, T & Taga, T (1996) Accelerated nerve regeneration in mice by upregulated expression

of interleukin (IL) 6 and IL-6 receptor after trauma J Exp Med.

183, 2627–2634.

56 Ma¨rz, P., Cheng, J.-C., Gadient, R.A., Patterson, P., Stoyan, T., Otten, U & Rose-John, S (1998) Sympathetic neurons can pro-duce and respond to interleukin-6 Proc Natl Acad Sci USA 95, 3251–3256.

57 Pennica, D., Arce, V., Swanson, T.A., Vejsada, R., Pollock, R.A., Armanini, M., Dudley, K., Phillips, H.S., Rosenthal, A., Kato, A.C & Henderson, C.E (1996) Cardiotrophin-1, a cytokine pre-sent in embryonic muscle, supports long-term survival of spinal motoneurons Neuron 17, 63–74.

58 Ma¨rz, P., Heese, K., Dimitriades-Schmutz, B., Rose-John, S & Otten, U (1999) Role of interleukin-6 and soluble IL-6 receptor in region specific induction of astrocytic differentiation and neuro-trophin expression Glia 26, 191–200.

59 Scha¨fer, K.H., Mestres, P., Ma¨rz, P & Rose-John, S (1999) The IL-6/sIL-6R fusion protein promotes neurite outgrowth and neuronal survival in cultured enteric neurons J Interferon Cyto-kine Res 19, 527–532.

60 Thier, M., Ma¨rz, P., Otten, U., Weis, J & Rose-John, S (1999) Interleukin-6 (IL-6) supports survival of sensory neurons: auto-crine trophic effects of IL-6 and soluble IL-6 receptor and enhanced activity of an IL-6 designer cytokine J Neurosci Res.

55, 411–422.

61 Ikeda, K., Iwasaki, Y., Tagaya, N., Shiojima, T & Kinoshita, M (1995) Neuroprotective effect of cholinergic differentiation factor/ leukemia inhibitory factor on wobbler murine motor neuron dis-ease Muscle Nerve 18, 1344–1347.

62 Aebischer, P., Schluep, M., Deglon, N., Joseph, J.M., Hirt, L., Heyd, B., Goddard, M., Hammang, J.P., Zurn, A.D., Kato, A.C., Regli, F & Baetge, E.E (1996) Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients Nat Med 2, 696–699.

63 Hottinger, A.F & Aebischer, P (1999) Treatment of diseases of the central nervous system using encapsulated cells Adv Technol Stand Neurosurg 25, 3–20.

64 Mittoux, V., Joseph, J.M., Conde, F., Palfi, S., Dautry, C., Poyot, T., Bloch, J., Deglon, N., O uary, S., Nimchinsky, E.A et al (2000) Restoration of cognitive and motor functions by ciliary neuro-trophic factor in a primate model of Huntington’s disease Hum Gene Ther 11, 1177–1187.

Ngày đăng: 22/02/2014, 07:20

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm